Envelope determinants of equine lentiviral vaccine protection.
Authors: Craigo Jodi K, Ezzelarab Corin, Cook Sheila J, Chong Liu, Horohov David, Issel Charles J, Montelaro Ronald C
Journal: PloS one
Summary
# Editorial Summary: Envelope Determinants of Equine Lentiviral Vaccine Protection Developing effective vaccines against equine infectious anaemia virus (EIAV) remains challenging because the pathogen's envelope protein undergoes constant antigenic variation, allowing it to evade immune recognition. Craigo and colleagues investigated how closely the vaccine strain's envelope glycoprotein (gp90) must match the challenge virus to confer protection, using a series of chimeric viruses with mixed genetic backbones to pinpoint which envelope regions were critical for immunity. The findings revealed a striking inverse relationship: ponies vaccinated with homologous virus showed near-complete protection (100%), whilst protection dropped to approximately 40% when challenged with virus whose gp90 was 13% divergent; moreover, only the N-terminal region of the gp90 appeared essential for generating lower post-challenge viraemia and delayed disease onset, though matching this region alone could not replicate full protection afforded by the original vaccine strain. The work demonstrates that envelope structure and conformation matter substantially—in vitro viral characteristics do not reliably predict in vivo immune efficacy—and suggests that future vaccine development and protection studies require binding-focused antibody assays rather than exclusively neutralising assays, since non-neutralising antibodies may play a more significant role in controlling EIAV than currently appreciated. For practitioners, these findings underscore why matching vaccine strains to circulating field virus variants remains practically important, and highlight the complexity of lentiviral immunity beyond simple sequence homology.
Read the full abstract on PubMed
Practical Takeaways
- •EIAV vaccine efficacy depends critically on matching the envelope protein sequence between vaccine strain and circulating field virus; expect protection to wane as virus diverges genetically
- •For working equine operations, vaccine strain selection and monitoring of circulating EIAV variants in your region should inform vaccination strategy
- •Development of improved EIAV vaccines will require structural biology approaches and antibody assays that measure binding capacity, not just neutralizing ability
Key Findings
- •Homologous gp90 envelope protein between vaccine and challenge virus conferred ~100% protection from disease in immunized ponies
- •Protection declined to approximately 40% when challenge virus gp90 was 13% divergent from vaccine strain gp90
- •N-terminal gp90 homology alone significantly reduced post-challenge viral levels and delayed disease onset, but was insufficient for complete protection
- •Structural conformation of envelope immunogens is critical for vaccine protection independent of in vitro virulence